Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Southern California, Los Angeles, CA, USA.
Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Department of Oncologic Sciences, Morsani School of Medicine, University of South Florida, Tampa, FL, USA.
Eur J Obstet Gynecol Reprod Biol. 2021 Dec;267:256-261. doi: 10.1016/j.ejogrb.2021.11.020. Epub 2021 Nov 16.
Tumor spill during surgical treatment is associated with adverse oncologic outcomes in many solid tumors. However, in minimally invasive hysterectomy for endometrial cancer, intraoperative tumor spill has not been well studied. This study examined surgeon experiences and practices related to intraoperative tumor spill during minimally invasive hysterectomy for endometrial cancer.
A cross-sectional survey was conducted to the Society of Gynecologic Oncology. Participants were 220 U.S. gynecologic oncologists practicing minimally invasive hysterectomy for endometrial cancer. Interventions were 20 questions regarding surgeon demographics, surgical practice patterns (fallopian tubal ablation/ligation, intra-uterine manipulator use, and colpotomy approach), and tumor spill experience (uterine perforation with intra-uterine manipulator and tumor exposure during colpotomy).
Nearly half of the responding surgeons completed subspeciality training >10 years ago (50.5%), and 74.1% had annual surgical volume of >40 cases. The majority of surgeons used an intra-uterine manipulator during minimally invasive hysterectomies for endometrial cancer (90.1%), and 87.2% of the users have experienced uterine perforation with an intra-uterine manipulator. Almost all surgeons performed colpotomy laparoscopically (95.9%), and nearly 60% had experienced tumor spill while making colpotomy (59.8%). Nearly 10-15% of surgeons have changed their postoperative therapy as a result of intraoperative uterine perforation (11.8%) or tumor spill (14.5%). Surgeons infrequently ablated or ligated fallopian tubes prior to performing the hysterectomy (14.1%).
Our survey study suggests that many surgeons experienced intraoperative tumor spillage during minimally invasive hysterectomy for endometrial cancer. These findings warrant further studies examining its incidence and impact on clinical outcomes.
在许多实体瘤中,手术过程中的肿瘤播散与不良的肿瘤学结果相关。然而,在子宫内膜癌的微创子宫切除术中,术中肿瘤播散尚未得到充分研究。本研究检查了外科医生在微创子宫内膜癌子宫切除术中与术中肿瘤播散相关的经验和实践。
对妇科肿瘤学会进行了横断面调查。参与者为 220 名在美国行微创子宫内膜癌子宫切除术的妇科肿瘤医生。干预措施为 20 个关于外科医生人口统计学、手术实践模式(输卵管结扎/切断术、宫内操作器的使用和阴道切开术入路)以及肿瘤播散经验(宫内操作器导致的子宫穿孔和阴道切开术期间的肿瘤暴露)的问题。
近一半的应答外科医生在 10 年前以上完成了亚专科培训(50.5%),74.1%的外科医生每年的手术量超过 40 例。大多数外科医生在微创子宫内膜癌子宫切除术中使用宫内操作器(90.1%),其中 87.2%的使用者在使用宫内操作器时发生了子宫穿孔。几乎所有外科医生均经腹腔镜进行阴道切开术(95.9%),近 60%的外科医生在进行阴道切开术时发生了肿瘤播散(59.8%)。近 10-15%的外科医生因术中子宫穿孔(11.8%)或肿瘤播散(14.5%)而改变了术后治疗方案。外科医生在进行子宫切除术之前很少对输卵管进行烧灼或结扎(14.1%)。
我们的调查研究表明,许多外科医生在微创子宫内膜癌子宫切除术中经历了术中肿瘤播散。这些发现需要进一步研究以检查其发生率及其对临床结果的影响。